|
| Press Releases |
|
 |
|
| Tuesday, December 2, 2025 |
|
|
GEN 宣布針對阿茲海默症及其他神經退化性疾病之試驗藥物 SUL-238 取得全新第一期試驗正面數據 |
| 土耳其領先的專業製藥公司GEN Pharmaceuticals（GENIL.IS）今日宣布，其針對首創口服型線粒體靶向藥物候選物 SUL-238 於健康老年志願者中進行的安全性、耐受性及藥代動力學（PK）評估之第一期臨床試驗取得新進展。該研究成果於今日在美國加州聖地牙哥舉行的第 18 屆阿茲海默症臨床試驗大會（CTAD）發表。 more info >> |
|
|
GEN 宣布针对阿尔茨海默病及其他神经退行性疾病的试验性药物 SUL-238 取得新的积极 I 期临床试验数据 |
| 土耳其领先的专科制药公司GEN Pharmaceuticals（GENIL.IS）宣布，其针对首创口服线粒体靶向药物候选物 SUL-238 的安全性、耐受性和药代动力学（PK）的 I 期临床试验在健康老年志愿者中取得新的积极结果。该研究成果于今日在美国加利福尼亚州圣地亚哥举行的第 18 届阿尔茨海默病临床试验大会（CTAD）上公布。 more info >> |
|
|
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases |
| GEN Pharmaceuticals (GENIL.IS), Turkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. more info >> |
|
| Tuesday, July 29, 2025 |
|
|
GEN 與 Sulfateq BV 公佈治療阿茲海默症及其他神經退化性疾病的候選藥物 SUL-238 的第一階段臨床試驗正面結果 |
| GEN製藥公司（GENIL.IS）是土耳其領先的專業製藥公司，日前宣布其第一階段臨床試驗取得積極結果。該試驗旨在評估首創且新型的口服線粒體靶向候選藥物 SUL-238 在健康老年志願者中的安全性、耐受性以及藥代動力學（PK）表現。研究結果已在2025年阿茲海默症協會國際會議（AAIC®）上於多倫多公佈。 more info >> |
|
|
GEN 与 Sulfateq BV 公布治疗阿尔茨海默病及其他神经退行性疾病的候选药物 SUL-238 的第一阶段临床试验积极结果 |
| GEN制药公司（GENIL.IS）是土耳其领先的专业制药公司，日前宣布其第一阶段临床试验取得积极结果。该试验旨在评估首创且新型的口服线粒体靶向候选药物 SUL-238 在健康老年志愿者中的安全性、耐受性以及药代动力学（PK）表现。研究结果已在2025年阿尔茨海默病协会国际会议（AAIC®）上于多伦多公布。 more info >> |
|
| Monday, July 28, 2025 |
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases |
| more info >> |
|
| Wednesday, September 25, 2024 |
|
|
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis |
| GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Valuufy調査：日本の自動車メーカーにおけるインパクトに関するコミットメントと検証済み実績の間に55ポイントのギャップを確認
Feb 4, 2026 18:00: JST
|
|
|
The 55-Point Gap: Measuring What Matters in Automotive Impact
Feb 4, 2026 18:00 JST
|
|
|
Airwheel Introduces AI-Driven Rideable Smart Cabin Suitcase Solutions for the Next Generation of Global Travel
Feb 4, 2026 15:00: JST
|
|
|
Airwheel Introduces AI-Driven Rideable Smart Cabin Suitcase Solutions for the Next Generation of Global Travel
Feb 4, 2026 14:00 HKT/SGT
|
|
|
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 4, 2026 13:30 JST
|
|
|
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Feb 4, 2026 12:28 HKT/SGT
|
|
|
華泰經紀攜手菲律賓Aboitiz Power集團 臨港首啟2026全球統保路演 賦能共建「一帶一路」能源合作
Feb 4, 2026 12:26 HKT/SGT
|
|
|
Honda Co-developing Automobile SoC with U.S.-based Mythic to Accelerate Research to Enhance AI Computing Performance and Energy Efficiency
Feb 4, 2026 11:32 JST
|
|
|
東方大鵬今日始：解碼「功能飲料第一股」東鵬飲料的長期價值底色
Feb 4, 2026 10:04 HKT/SGT
|
|
|
东方大鹏今日始：解码"功能饮料第一股"东鹏饮料的长期价值底色
Feb 4, 2026 10:04 HKT/SGT
|
|
|
Casa Minerals Inc. Announces Closing of First Tranche of Private Placement
Feb 4, 2026 07:59 HKT/SGT
|
|
|
先導智能赴港招股：新能源裝備龍頭 開啟全球增長新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
先导智能赴港招股：新能源装备龙头 开启全球增长新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
卡奧斯遞表港交所：工業數智化龍頭 為製造業培育新質生產力注入強勁動能
Feb 3, 2026 19:20 HKT/SGT
|
|
|
DENSO Announces Third Quarter Financial Results
Feb 3, 2026 19:36 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
